Colorectal cancer — patterns of locoregional recurrence and distant metastases as demonstrated by FDG PET/CT

Nilendu C Purandare, Sumeet G Dua, Abhishek Arora, Sneha Shah, Venkatesh Rangarajan
Bio-Imaging Unit, Tata Memorial Hospital, Dr. Ernest Borges Marg, Parel, Mumbai- 400 012, India

Correspondence: Dr. Venkatesh Rangarajan, Bio-Imaging Unit, Tata Memorial Hospital, Dr. Ernest Borges Marg, Parel, Mumbai- 400 012, India. E-mail: drvrangarajan@gmail.com

Abstract

Colorectal cancer (CRC) can recur locoregionally or at distant sites. Timely diagnosis of recurrence is of paramount importance, as radical treatment of the localized disease can prolong survival. Fluorodeoxyglucose positron emission tomography / computed tomography (PET/CT) is routinely used in restaging and surveillance of colorectal cancer, as it can demonstrate recurrent disease with good accuracy. This article illustrates the spectrum of standard as well as unusual patterns of local recurrence and distant metastases of colorectal cancer.

Key words: Fluorodeoxyglucose (FDG) PET/CT; colorectal cancer; recurrence disease

Introduction

Recurrence of colorectal cancer (CRC) is seen in about 30–40% of patients who undergo primary curative surgical resection. The majority of these recurrences occur in the first two years after surgery. Radical treatment of isolated local recurrences and hepatic and pulmonary metastases has been shown to improve survival; however, such interventions, in the presence of metastases at other sites, have failed to result in significant survival advantage. Hence, imaging can play a very important role in detecting early recurrent disease, while the recurrence is still localized and resectable.

Local or locoregional recurrence
Pelvic recurrence in operated CRC occurs in as much as 30% of the cases. Recurrence may be seen in the pelvic nodes, at the anastomotic site or rectal stump, or in the presacral area, as a soft tissue mass. The importance of early detection of local recurrence at an operable stage cannot be overemphasized, in view of literature reports showing improved survival following resection of localized recurrences.

Presacral and pelvic soft tissue recurrence
Surgery for CRC and radiation therapy-associated inflammatory changes can lead to both anatomic distortion in the pelvis, and often predispose to the development of a fibrotic presacral mass. This can occur in as many as 39% of the patients following anterior resection and in 19% of the patients after abdominoperineal resection. CT scanning, due to its reliance on size and morphology, has limitations differentiating between fibrotic masses and soft tissue recurrences. On FDG-PET imaging, a recurrent mass in the presacral region shows increased tracer uptake, thus differentiating it from the fibrotic tissue. PET/CT has shown higher accuracy when compared to PET and CT scan individually in differentiating a fibrotic presacral mass from recurrent disease. Although FDG uptake shows disease in CT scan negative areas, a CT scan...
often solves the problem of physiological FDG uptake in normal structures such as the urinary bladder and bowel, which prolapse into the empty rectal fossa and may give rise to false positive PET results. In the perianal and rectal stump regions, however, the CT scan has limited contrast resolution and FDG-PET can be very useful in picking up subtle recurrence [Figure 3].

**Anastomotic site recurrences**

Recurrence at the anastomotic site is often encountered. Resection of such localized recurrences offers a survival advantage. The typical PET / CT appearance is of a hypermetabolic soft tissue mass or subtle wall thickening at the anastomotic site,[10] which is often identified by a surgical ring of radio-opaque staples [Figure 4]. Although colonoscopy would be the ideal technique for diagnosing and confirming anastomotic site recurrences, FDG PET / CT imaging can prove to be an excellent noninvasive modality when such recurrences are suspected.

**Pelvic nodal recurrence**

Categorization of nodes as metastatic on conventional imaging modalities, including CT scan and magnetic resonance imaging (MRI), is based on their size. This approach results in a decrease in the reporting of metastatic recurrence in centimeter-sized nodes, which are often seen in CRC. By virtue of its ability to superimpose metabolic information on the anatomic detail, the PET / CT helps characterize even centimeter-sized metastatic nodes [Figure 5], with a resultant reduction in false negative restaging studies.[11]

**Distant metastases**

**Liver and lung metastases**

Resection of operable hepatic and pulmonary metastases offers the only chance of cure and serves to prolong survival in CRC; however, the presence of extrahepatic or extrapulmonary metastases is associated with poor survival despite metastatectomy. According to a recent prospective multicenter study, which evaluated the role of FDG-PET in recurrent colorectal cancer, 23.5% of the patients with potentially resectable hepatic and pulmonary metastases, on conventional imaging, were deemed inoperable as a result of their PET scan findings.[12] As mentioned earlier, the PET...
CT can detect occult metastases in about one-third of the patients with CRC, and thereby alter the management.\[13\]

In a meta-analysis, when comparing FDG-PET, CT scan, and 1.5 T MRI in colorectal liver metastases, FDG was found to be the most accurate modality on a per-patient basis, whereas, the modalities were more or less comparable on a per-lesion basis.\[14\] However, the MRI using liver-specific contrast agents was found to be superior to FDG-PET in the detection of small liver metastases.\[15\] In addition, PET/CT also showed significantly higher specificity (100%) than the contrast-enhanced CT scan (50%) in the detection of recurrences following hepatic resection,\[16\] as well as following radiofrequency ablation (RFA).\[17\] Complete photopenia at the ablated site on the FDG-PET scan suggested a metabolic response and completeness of the ablation\[18,19\] [Figure 6].

**Peritoneal deposits**

The development of peritoneal disease [Figures 7 and 8] in the setting of CRC carries a grave prognosis, with little — if any — response to surgical therapy or chemotherapeutic agents.\[20\] The prognosis is slightly better in the localized foci of peritoneal disease, as they are amenable to complete resection and thus call for accurate and timely detection.\[20,21\] Occasionally these deposits can result in bowel adhesion and consequent intestinal obstruction [Figure 8].

**Abdominal wall and colostomy site recurrence**

Scars from open or laparoscopic surgery, as well as drain, port, and stoma sites, are potential locations of metastatic CRC recurrence [Figure 9]. Resection of such metastases...
Figure 10 (A-F): Restaging FDG PET / CT studies performed on two different patients of treated CRC. Axial PET (A), axial CT scan (B), and fused axial PET / CT (C) images show multiple FDG-avid lung metastases. Axial fused PET / CT images of another patient of CRC show FDG-avid skeletal metastases in the left sacral ala (arrow in D), D8 vertebral body (arrow in E), and in the left transverse process of the D1 vertebra (arrow in F).

Figure 11 (A-C): Restaging FDG PET / CT studies performed on three different patients of treated CRC for suspicion of disease recurrence show unusual metastatic sites; in the right lobe of the thyroid gland (arrow in A), in the subcutaneous region of the left upper arm (arrow in B), metastatic portal adenopathy (arrowhead in C), and a right adrenal metastasis (arrow in C).

Figure 12 (A,B): A 52-year-old man with metastatic CRC imaged with FDG PET / CT before and after targeted therapy. Fusion PET / CT study (A) prior to targeted therapy shows an FDG-avid metastatic retroprostatic nodule (arrow). There is significant reduction in the metabolism and size of the recurrent nodule (arrow) on the post-therapy follow-up PET / CT image (B), suggesting therapeutic response.

Infrequent sites
The incidence of metastases to infrequent sites is increasing due to the improved survival of patients. Skeletal [Figures 10D-F] and brain metastases are more likely to occur in the setting of lung metastases, [Figures 10A-C] and in a primary rectal cancer as compared to colon cancer.[25] Occasional cases of metastases from CRC to thyroid,[26] can be considered in the absence of disease in the abdomen or elsewhere as it can result in adequate local control with minimal procedural complications.[22,23] PET / CT is a sensitive tool in the detection of abdominal wall, stoma / port-site metastases of CRC.[24]
adrenals,"\cite{27}" and subcutaneous tissues\cite{28} [Figure 11] have also been documented in literature.

**FDG-PET in monitoring response to systemic therapy**

Morphological imaging techniques are limited in assessing therapeutic response, as they rely on changes in tumor size, which often lag behind biological response. FDG-PET has been used to monitor early response to primary as well as secondary chemotherapeutic agents after the first or the second cycle in advanced CRC\cite{29} [Figure 12]. Furthermore, with the advent of newer molecular targeted therapies that often target biological effects like angiogenesis, more accurate surrogate endpoints are required, to assess therapeutic response. FDG PET / CT can be very useful in this regard to identify responders early in the course of therapy.

**References**

1. Galandiu S, Wied HS, Moertel CG, Cha SS, Fitzgibbons RJ Jr, Pemberton JH, et al. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet 1992;174:27-32.
2. Viganò L, Ferrero A, Lo Tesoriere R, Capussotti L. Liver surgery for colorectal metastases: results after 10 years of follow-up. Long-term survivors, late recurrences, and prognostic role of morbidity. Ann Surg Oncol 2008;15:2458-64.
3. Pfannschmidt J, Dienesch M, Hoffmann H. Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series. Ann Thorac Surg 2007;84:324-38.
4. Gayowski TJ, Iwatsuki S, Madariaga JR, Selby R, Todo S, Irish W, et al. Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery 1994;116:703-10.
5. Delbeke D, Vitola JY, Sandler MP, Arlidsen RC, Powers TA, Wright JK Jr, et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med 1997;38:1196-201.
6. Flamen P, Hoekstra OS, Homans F, Van Cutsem E, Maes A, Stroobants S, et al. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). Eur J Cancer 2001;37:862-9.
7. Quentmeier A, Schlag P, Smok M, Herfarth C. Re-operation for recurrent colorectal cancer: the importance of early diagnosis for resectability and survival. Eur J Surg Oncol 1990;16:319-25.
8. Huguet M, Houry S, Barrier A. Local recurrence of cancer of the rectum. Am J Surg 2001;182:437-9.
9. Ogunbiyi OA, Flanagan FL, Dehdashi F, Siegel BA, Trask DD, Birnbaum EH, et al. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol 1997;4:613-20.
10. Shyn PB, Madan R, Wu C. PET/CT pattern analysis for surgical staple line recurrence in patients with colorectal cancer. AJR Am J Roentgenol 2010;194:414-21.
11. Tsunoda Y, Ito M, Fujii H, Kuwano H, Saito N. Preoperative diagnosis of lymph node metastases of colorectal cancer by FDG-PET/CT. Jpn J Clin Oncol 2008;38:347-53.
12. Scott AM, Gunawardana DH, Kelley B, Stuckey JG, Byrne AJ, Ramshaw JE, et al. PET changes management and improves prognostic stratification in patients with recurrent colorectal cancer: results of a multicenter prospective study. J Nucl Med 2008;49:1451-7.
13. Watson AJ, Lolohea S, Robertson GM, Frizelle FA. The role of positron emission tomography in the management of recurrent colorectal cancer: a review. Dis Colon Rectum 2007;50:102-14.
14. Bipat S, van Leeuwen MS, Comans EF, Fijl ME, Bossuyt PM, Zwijnderman AH, et al. Colorectal Liver Metastases: CT, MR Imaging, and PET for Diagnosis-Meta-analysis. Radiology 2005;237:123-31.
15. Kong G, Jackson C, Koh DM, Lewington V, Sharma B, Brown G, et al. The use of 18F-FDG PET/CT in colorectal liver metastases—comparison with CT and liver MRI. Eur J Nucl Med Mol Imaging 2008;35:1323-9.
16. Selzner M, Hany TF, Wildbrett P, McCormack L, Kadry Z, Clavien PA. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 2004;240:1027-34.
17. Travaili LL, Trifirò G, Ravasi L, Monfardini L, Della Vigna P, Bonomo G, et al. Role of [18F] FDG-PET/CT after radiofrequency ablation of liver metastases: preliminary results. Eur J Nucl Med Mol Imaging 2008;35:1316-22.
18. Khandani AH, Calvo BF, O’Neil BH, Jorgenson J, Mauro MA. A pilot study of Early 18F- FDG PET to evaluate the effectiveness of radiofrequency ablation of liver metastases. AJR Am J Roentgenol 2007;189:1199-202.
19. Kuehl H, Antoch G, Stergar H, Veit-Haibach P, Rosenbaum-Krumme S, Vogt F, et al. Comparison of FDG-PET, PET/CT and MRI for follow-up of colorectal liver metastases treated with radiofrequency ablation: Initial results. Eur J Radiol 2008;67:362-71.
20. Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 1995;221:124-32.
21. Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol 1999;43:SI5-25.
22. Silecchia G, Ferrotta N, Giraudo G, Salvai M, Parini U, Felicitti F, et al. Abdominal wall recurrences after colorectal resection for cancer: Results of the Italian registry of laproscopic colorectal surgery. Dis Colon Rectum 2002;45:1172-7.
23. Koea JB, Lanouette N, Paty PB, Guilm FM, Cohen AM. Abdominal wall recurrence after colorectal resection for cancer. Dis Colon Rectum 2000;43:628-32.
24. Goshen E, Davidson T, Aderka D, Zwas ST. PET/CT detects abdominal wall and port site metastases of colorectal carcinoma. Br J Radiol 2006;79:572-77.
25. Sundermeyer ML, Meropol NJ, Rogatko A, Wang H, Cohen SJ. Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer 2005;5:108-13.
26. Hanna WC, Ponsky TA, Trachtlos GD, Knoll SM. Colon cancer metastatic to the lung and the thyroid gland. Arch Surg 2006;141:93-6.
27. Murakami S, Terakado M, Hashimoto T, Tsuji Y, Okubo K, Hirayama R. Adrenal metastasis from rectal cancer: report of a case. Surg Today 2003;33:126-30.
28. Hyun IY, Yun MY. FDG uptake in cutaneous and subcutaneous metastases from colorectal adenocarcinoma. Clin Nucl Med 2010;35:93-4.
29. Dimitrakopoulou-Strauss A, Strauss LG, Rudi J. PET FDG as predictor of therapy response in patients with colorectal carcinoma. Q J Nucl Med 2003;47:8-13.

**Source of Support:** Nil. **Conflict of Interest:** None declared.